Keywords: fda, puts, clinical, hold, valopicitabine, over, risk/benefit
FDA puts clinical hold on valopicitabine over risk/benefit profile; Idenix plunges 34%
Article | 23 July 2007
Swiss drug major Novartis and USA-based Idenix Pharmaceuticals have suspended trials of their co-developed hepatitis C drug, valopicitabine (MN283), after ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
